Photocure ASA: Results for the second quarter of 2025

About this update from Photocure Asa

[{"type":"text","content":"OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and an EBITDA of NOK 14.8 million (Q2 2024: NOK 27.8 million, including a milestone payment of NOK 21.6 million) for the company. Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in milestones this year.","length":648,"tagName":"p"},{"type":"text","content":""We delivered all-time high Hexvix/Cysview revenues, and the ninth consecutive quarter of positive EBITDA, while continuing to make smart decisions that accelerate and drive the topline growth. The Q2 results are driven by the solid performance from our U.S. franchise where the team continues to increase the number of active accounts by 24%. We continue to offset the decline in flexible cystoscopy kits and expect the U.S. unit growth to accelerate in 2025 onwards. In the second quarter alone, the rigid kit sales increased by 21 percent, " says Dan Schneider, President & Chief Executive Officer of Photocure.","length":633,"tagName":"p"},{"type":"text","content":"The company continued to execute on its plan to expand blue light cystoscopy use in Q2 2025 with the installation of 12 new Saphira™ towers in the U.S. — 3 new accounts and 9 blue light tower upgrades. With the increasing momentum provided by ForTec's mobile solution, Photocure had 359 active accounts in the U.S. at the end of the quarter, an increase of 24% versus the second quarter of 2024.","length":399,"tagName":"p"},{"type":"text","content":"Across Europe, a total of 36 Olympus Visera Elite III blue light cystoscopy (BLC) capable systems were installed since the launch in Q1 2025.","length":141,"tagName":"p"},{"type":"text","content":""We fully expect this new state-of-the art equipment to fuel Hexvix growth in the Nordic region and throughout continental Europe this year and beyond,"  Schneider adds.","length":184,"tagName":"p"},{"type":"text","content":"Photocure believes that the benefits of Blue Light Cystoscopy with Hexvix®/Cysview®&n...

More updates from Photocure Asa